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INTRODUCTION
Portal hypertension occurring during the natural course of liver cirrhosis is a conse-
quence of the increased intrahepatic resistance to portal flow. For a long time, this phe-
nomenon has been ascribed only to the profound changes of liver tissue angioarchitecture
consequent to the progression of the fibrogenic process. However, studies performed
during the last decade have demonstrated that there is also an increased vascular tone that
could be modulated to a certain extent by pharmacological agents. The aim of this chap-
ter is to provide general information on the anatomy of the portal systems and on the
regulation of vascular tone in this specific vascular district and in the splanchnic circu-
lation. Information about the collateral circulation that becomes relevant in the case of
portal hypertension is also provided.
In addition, because of the many studies performed in animal models and isolated and
cultured hepatic cell, attention will be paid to the biology of these cells and to the relative
pathophysiological implications. In particular, hepatic stellate cells, now regarded as
liver-specific pericytes, are likely to play an important role in the progression of portal
hypertension because of their active role in the deposition of fibrillar extracellular matrix
and of their contractile properties. In this context, several vasoconstricting agonists,
whose expression is increased in fibrotic liver, may play a role in inducing contraction
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of hepatic stellate cells as well as of other resident cells characterized by contractile abil-
ity. The features of different vasoactive agents will be analyzed and their potential involve-
ment in physiological and pathological conditions thoroughly discussed.
ANATOMIC CONSIDERATIONS
OF THE NORMAL PORTAL CIRCULATION
A portal venous system is defined as one beginning and ending in capillaries. The name
“portal vein” derives from the notion that it is the gate into which the splanchnic circu-
latory system is connected to the liver (porta = gate). The name portal vein is applied
to the venous system that originates in the capillaries of the intestine and terminates in
the hepatic sinusoids. Nutrients absorbed from the gastrointestinal tract, in addition to
hormones such as glucagons and insulin released by the pancreas, are directly delivered
to the liver in high concentrations.
Embryology of the Portal System
The portal venous system originates from the two vitelline and the two umbilical veins.
The vitelline veins, which drain blood from the yolk sac, intercommunicate in the septum
trasversum, at which point the liver sinusoids and lobules develop. The extrahepatic
portal system develops primarily from the left vitelline vein (which is later joined by the
splenic vein to form the portal vein), whereas the intrahepatic portal circulation origi-
nates from the umbilical veins. In addition, the left umbilical vein communicates with the
venous sinus connecting with the inferior vena cava, thus allowing a large quantity of
blood to bypass the liver in the fetal circulation. Soon after birth, the umbilical vein is
obliterated and the normal adult circulation is established. Despite this complexity in the
development of the portal system, only very few congenital anomalies of the portal venous
system are observed.
Gross Anatomy of the Portal System
The portal vein is a vessel collecting the venous blood of the abdominal part of the
alimentary tract, spleen, pancreas, and gallbladder to the liver. The portal vein begins at
the level of the second lumbar vertebra, just behind the neck of the pancreas as an upward
continuation of the superior mesenteric vein after this vessel has been joined by the splenic
vein. The superior mesenteric vein (0.78 cm in diameter) is primarily formed by all the
veins draining the small bowel, with significant further contributions of the ileocolic,
right colic, and middle colic veins. It runs in the root of the mesentery, in front of the third
portion of the duodenum to merge with the splenic vein. The splenic vein (0.94 cm in diam-
eter) originates with five to six branches that return the blood from the spleen and unite
to form a single nontortuous vessel at the splenic hilum and join near the tail of the pancreas
with the short gastric vessels to form the main splenic vein. This vein proceeds transvers-
ally, close to the hilum of the left kidney, in the body and head of the pancreas, receiving
numerous tributaries from this latter portion of the pancreas. The left gastroepiploic vein
joins the splenic vein near the spleen, and the inferior mesenteric vein (0.24 cm diameter),
collecting blood from the left part of the colon and rectum, usually enters its middle third.
Occasionally (one-third of subjects) the inferior mesenteric vein enters directly into the
superior mesenteric vein or at its junction with the splenic vein. On its way to the porta
hepatis, the portal vein trunk receives (in some variants) the superior pancreaticoduodenal
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vein (with right gastroepiploic vein) and the right gastric (pyloric) veins. The left gastric
(coronary) vein joins the portal vein at its origin 50% of the time, and it joins the splenic
instead of the portal vein in the other 50% of subjects. Coronary vein runs upward along
the lesser curvature of the stomach, where it receives some esophageal veins.
The portal system carries all the blood from the alimentary tract to the liver and, thus,
in the normal subject all of the above-named veins have blood flow directed toward the
liver. The segment of the portal vein after the last afferent branch runs in the hepatodu-
odenal ligaments (the free edge of the lesser omentum) in a plane dorsal to the bile ducts
and the hepatic artery. This segment extends for approx 6–8 cm before entering the liver
and it is 1–1.2 cm in diameter. The portal vein is not provided with valves, so the pressure
is transmitted freely back to the afferent branches. The portal vein pressure normally ranges
between 5 and 10 mmHg (depending on the method of measurement). Normal fasting
hepatic blood flow is approx 1500 mL/min. The best available estimates in humans indi-
cate that about two-thirds of the total hepatic blood flow and about one-half of the oxygen
consumption are supplied by the portal vein, whereas the remainder is supplied by the
hepatic artery. This dual hepatic blood supply makes the liver rather resistant to hypoxia.
Accordingly, ligation of the portal vein does not cause hepatocellular necrosis. Simi-
larly, accidental ligation of the hepatic artery or its major branches does not necessarily
lead to hepatic failure. The portal trunk divides into two lobar veins before entering the
portal fissure. The right lobar branch, short and thick, then receives the cystic vein. The
left lobar vein is longer than the right and consists of a transverse and an umbilical part.
The latter is the remainder of the umbilical parts. The recanalized umbilical or paraum-
bilical veins arise from the umbilical portion of the left portal vein and pass through the
round ligament to the anterior abdominal wall, where they may become evident, in the
presence of portal hypertension, in the umbilical varices.
According to the distribution of major portal vein branches, so-called segmental branches,
the liver can be divided into functional segments. Each segment depends on its major
vessel for blood supply. The right branch of the portal vein is usually less than 3 cm long
and runs more vertically. It divides into anterior and posterior branches, which supply
the anterior and posterior parts of the right lobe. Each of these vessels divides again into
superior and inferior branches. The left lobar vein gives branches to the quadrate lobe and
to the caudate lobe, before entering the parenchyma at the left end of the porta hepatis. A
separate branch may arise near the bifurcation to supply the caudate lobe. The vein is then
joined by the obliterated umbilical vein as it turns medially. The terminal part of the ves-
sel continues into segment IV, which it supplies with ascending and descending branches.
In addition to the main portal vein and its branches, the liver receives other veins from the
splanchnic circulation, the so-called parabiliary venous system of Couinaud. This highly
variable plexus includes several veins that arise from the pancreaticoduodenal or pyloric
veins and drain into the portal vein or directly into hepatic segments, especially segment
IV. This plexus provides examples of the metabolic effects of proximity to an insulin
source. Veins arising from the pancreatic region would carry blood with high insulin levels
and pyloric veins would carry low-insulin blood. The anatomy of these veins could explain
some examples of focal fatty liver and focal fatty sparing, in fact, insulin determines the
ability of the liver to accumulate triglycerides (1).
The other vessel supplying the liver is the hepatic artery. About one-third of the total
hepatic blood flow is supplied by the hepatic artery. The common hepatic artery is the
second major branch of the celiac axis. It runs to the right along the upper border of the
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pancreas in the context of the right gastropancreatic fold, which conducts the artery to
the medial border of the hepatoduodenal part of the lesser omentum. It ascends in front
of the portal vein in 91% of subjects and to the left of and behind the bile duct in 64%
of cases. It divides into the left and the right hepatic arteries to supply the corresponding
hemilivers. Although the left and right hepatic arteries are end-arteries, they often anas-
tomose within the hilar tissue (2). The right and left hepatic arteries each divide into two
arteries that supply the right anterior and posterior sections and the left medial lateral
sections, respectively. Another branch, the middle hepatic artery, arises from the left or
right hepatic artery and supplies the quadrate lobe. The cystic artery arises from the right
hepatic artery in the upper part of the Calot triangle (formed by the cystic duct, common
hepatic duct, and inferior surface of liver) (3).
Portal Collateral Circulation
The portal system has numerous collaterals that interconnect with the systemic circu-
lation. When portal pressure rises above 10 mmHg potential portosystemic collaterals may
develop. Formation of collaterals is a complex process involving the opening, dilation,
and hypertrophy of preexisting vascular channels. It is possible that active neoangiogen-
esis is involved in the formation collateral vessels (4). The sites for the development of
portal collateral vessels are those areas where veins draining into the portal system are in
immediate juxtaposition to veins draining into the superior or inferior vena cava. Collat-
erals vessels could be classified into tree embryological groups: (1) junction of absorp-tive
and protective epithelium (gastroesophageal and hemorrhoidal plexuses); (2) obliterated
fetal circulation (umbilical or paraumbilical veins in round and falciform ligaments); and
(3) organs derived from the gastrointestinal tract that became retroperitoneal or adhere
to the abdominal wall because of pathologic process (portorenal plexus, veins of Retzius,
surgical stomata, and other interventions connecting portal bed with the ascending lum-
bar azygos, renal, and adrenal veins).
The most important sites for the development of portosystemic collateral vessels are:
(1) esophageal submucosal veins, supplied by the left gastric vein and draining into the
superior vena cava through the azygos vein; (2) paraumbilical veins, although normally
nonfunctional, can serve as an anastomosis between the umbilical part of the left portal
vein and the hepigastric veins of the anterior abdominal wall that drain into the superior
or inferior vena cava, and in special circumstances may form caput medusae at the umbi-
licus (Cruveilhier–Baumgarten syndrome); (3) rectal submucosal veins, supplied by the
inferior mesenteric vein through the superior rectal vein and draining into the internal
iliac veins through the middle rectal vein; (4) splenorenal shunts, in this case venous blood
may be carried to left renal vein, either directly or by way of the diaphragmatic, pancrea-
tic, or gastric veins; (5) short gastric veins communicate with the esophageal plexus. More-
over, within the cirrhotic liver, there is significant collateral flow in small veins that con-
nect branches of the portal and hepatic veins (5).
The Gastroesophageal Junction
The normal venous anatomy of the gastroesophageal junction and of the lower esopha-
gus is particularly relevant to this introductory chapter. Studies of Vianna et al. docu-
mented four distinct zones of esophageal venous drainage (from distal to proximal): (1)
the gastric zone, which extends for 2–3 cm just below the gastroesophageal junction. This
is the junctional zone between the stomach and lower oesophagus. Veins from this zone
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drain into the short gastric and left gastric veins. (2) The palisade zone extends 2–3 cm
superiorly from the gastric zone into the lower esophagus and represent the watershed
between the portal and systemic circulation. (3) The perforating or transitional zone ex-
tends approx 2 cm further up the esophagus above the palisade zone. Here, the organized
longitudinal structure is lost, with veins looping and forming a network. The main fea-
ture of this zone is represented by the presence of perforating veins through the muscle
wall of the esophagus linking the submucosal and paraesophageal venous plexuses that are
tributaries of the azygos venous system. These perforating veins run circumferentially
around the esophageal wall. In portal hypertensive patients, dilated perforating veins
become incompetent and allow retrograde blood flow from the paraesophageal to the sub-
mucosal veins. This associated with the turbulent flow caused by pressure changes as a
result of the respiratory movements, coughing and stretching may contribute to forma-
tion and dilation of varices. (4) The truncal zone is 8–10 cm long and is characterized by
four of five longitudinal veins in the lamina propria. In this zone, perforating veins pene-
trate from the submucosa at irregular intervals to the external esophageal venous plexus.
In summary, venous drainage from the gastric fundus and the lesser curvature is directed
inferiorly to the portal vein. In the palisade zone, there is to/from flow that is probably
respiration dependent. The perforating veins connect the intrinsic and extrinsic esopha-
geal plexuses. Flow in the truncal zone is inferior to the perforating zone. In conclusion,
the perforating, transitional zone is the “critical area” for variceal rupture. Indeed, varices
tend to be bigger and to form “nodules” at the distal end of the esophagus, at the level
of the perforating veins (6).
Structure and Function
of the Splanchnic Vasculature
The splanchnic circulation consists of those vascular beds perfused by the celiac,
superior and inferior mesenteric arteries, and the portal vein. The organs perfused by the
splanchnic vasculature receive about 25% of cardiac output and account for about 30%
of total body oxygen consumption under resting conditions. Functional and/or structural
changes in arterioles, capillaries, and venules can initiate or perpetuate an elevated portal
pressure (e.g., dilation of arterioles, passive occlusion of capillaries, and active constric-
tion of hepatic venules). The structural and functional characteristics of the microvas-
culature of the stomach and small and large intestine are very different from those of the
liver. First, splanchnic capillaries are much less porous than the hepatic sinusoids and
have a well-defined basement membrane. Although most splanchnic capillaries are fen-
estrated, the estimated pore size, 3.7 to 12 nm in radius, is between 50 and 100 times
lower than that of the hepatic sinusoids. A very little amount of the total protein oncotic
pressure may pass across a splanchnic capillary membrane; consequently, any increase
in filtration in the splanchnic capillaries is quickly counterbalanced by an increase in the
oncotic pressure difference between capillary lumen and interstitial space. In addition,
there is evidence that the intestinal microvasculature autoregulates the capillary pres-
sure and capillary filtration coefficient. There are significant differences between the
intestinal and hepatic interstitium in terms of compliance; in fact, considerable interstitial
fluid can accumulate without causing any major changes in interstitial pressure. More-
over, the intestines have a very efficient lymphatic system to remove interstitial edema.
In normal conditions, approx 20% of the fluid absorbed by the small intestine is carried
out to the general circulation by the lymphatics (7).
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Under basal conditions, splanchnic arterioles are partially constricted, and have the
capacity to either further constrict or dilate. This arteriolar smooth muscle tone is the
sum of multiple factors that tend to either relax or constrict vascular smooth muscle. A
variety of metabolic end-products (e.g., adenosine), some endothelium-derived substances
(e.g., nitric oxide), and certain neurotransmitters (e.g., acetylcholine) are known to relax
arteriolar smooth muscle and produce vasodilation. Important vasoconstrictors influences
on splanchnic arterioles include some circulating agents (e.g., angiotensin II), certain
endothelium-derived substances (e.g., endothelin), and some neurotransmitters (norepi-
nephrine). These factors can alter the contractile state of arteriolar smooth muscle either
by acting directly on vascular smooth muscle (e.g., metabolic mediators) or by stimu-
lating endothelial cells to release vasoactive agents that act on the underlying adjacent
vascular smooth muscle (e.g., acetylcholine). Hypoxia, in terms of reduced oxygen deliv-
ery or increased oxygen demand, can lead to changes in arteriolar tone and consequent
changes in blood flow. This effect appears to be mediated by terminal products of oxi-
dative metabolism, such as adenosine, and tissue oxygen tension (pO2) and appear to be
one of the principal mechanisms of postprandial hyperemia. In fact, when tissue pO2
falls or extracellular adenosine concentration rises, arterioles dilate. Normally, splanch-
nic arterioles are exquisitely sensitive to acute changes in intravascular pressure. Vascu-
lar smooth muscle of splanchnic arterioles contracts intensely in response to stretch (induc-
ing a sudden elevation in portal pressure). The intense dilation of arterioles observed in
chronic portal hypertension likely reflects the accumulation of vasodilators [e.g., increased
nitric oxide (NO) production, increased blood levels of glucagons] that overcome intrin-
sic myogenic vasoconstrictor factors (8).
Norepinephrine, angiotensin II, and vasopressin are estimated to account for more than
two-thirds of basal splanchnic vascular tone. Norepinephrine generally elicits a profound,
yet transient, reduction in splanchnic blood flow. Increased tissue levels of adenosine
during vasoconstriction-mediated arterioles escape from norepinephrine-mediated vaso-
constriction. On the contrary, vasopressin and angiotensin II cause a sustained reduction
in splanchnic blood flow. Glucagon attenuates the splanchnic vasoconstrictive response
induced by catecholamines, vasopressin, and angiotensin II through a downregulation
of receptors and/or postreceptor mechanisms such as impairment of second-messenger
activation in splanchnic vascular smooth muscle. A wide variety of hormones and pep-
tides produced within the alimentary tract are capable of altering splanchnic blood flow
when infused into arterial blood. Somatostatin and neuropeptide-Y are locally produced
peptides that exert potent vasoconstrictor actions. Vasoactive intestinal polypeptide, sub-
stance P, cholecystokinin, and gastrin are examples of gastrointestinal peptides that dilate
splanchnic arterioles and increase blood flow.
Splanchnic organs exhibit an intrinsic ability to regulate local blood flow by modulat-
ing the tone of arterioles. Two examples of intrinsic vasoregulation are pressure-flow auto-
regulation and functional (postprandial) hyperemia. Pressure-flow autoregulation is the
ability of an organ to maintain its constant blood flow when arterial pressure is reduced.
This regulatory mechanism depends on metabolic or myogenic-mediated dilation of arte-
rioles at lower intravascular pressures. However, pressure-flow autoregulation of splanch-
nic organs is not as potent and precise as in other vascular beds such as the heart, the
brain, and the kidneys. Nevertheless, this autoregulation is improved in the postprandial
phase (increased metabolic demand), when arterioles become more sensible to reductions
in arterial pressure. Postprandial hyperemia has recently received much attention as a
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potential cause of rapid elevation in splanchnic blood flow and portal pressure that may
lead to variceal formation, dilation, and explosion (9,10). Splanchnic vasodilation and
hyperemia is caused by the interaction of intrinsic (change in arteriolar transmural pres-
sure and/or increase in vasodilator tissue metabolites) or extrinsic mechanisms (auto-
nomic nervous system especially noncholinergic vagal reflexes) and the effect of nitric
oxide, gastrointestinal hormones and peptides (gastrin, cholecystokinin and glucagons),
autacoids (histamine, serotonin), osmolality, and prostaglandins. The relative contribu-
tion of these different factors is influenced by the composition of the meal (i.e., long-chain
fatty acids appear to be the most potent stimulus) and the preprandial metabolic status
of the affected organ.
Nerves
The liver is predominantly innervated by two plexuses, the anterior and the posterior,
which communicate with each other. The anterior plexus surrounds the hepatic artery and
is made up of fibers from the celiac ganglia and anterior vagus nerve. The posterior plexus
surrounds the portal vein and bile duct and is formed from branches of the right celiac
ganglia and posterior vagus. The vast majority of nerve fibers terminate in plexuses in the
adventitia around hepatic arterioles and venules. Small fibers from these plexuses then
end on smooth muscle cells in the media of these vessels. Within the liver cell plate, the
majority of nerve fibers are observed in periportal regions. Some of the nerve fibers ter-
minate on endothelial cells in the smallest hepatic arterioles, near the space of Disse, on
Kupffer cells, and on hepatic stellate cells (HSC).
Hepatic innervation can be distinguished in extrinsic and intrinsic. The extrinsic inner-
vation of the liver is constituted by: (1) efferent sympathetic nerve fibers and parasym-
pathetic nerve fibers; these play a role in regulating the metabolic load of hepatocytes,
hemodynamic and biliary motility; (2) afferent fibers, which are thought to be involved
in osmo- and chemoreception. At the hilus, amyelinic fibers from the anterior and pos-
terior plexuses enter the liver mainly around the hepatic artery. The intrinsic innervation
is composed of fibers (mostly adrenergic, but also cholinergic and peptidergic) mainly
associated with vascular and biliary structures in the portal spaces (11). Certain fibers enter
liver lobule where they form a network around hepatocytes and extend into the sinusoidal
wall, sometimes reaching the centrilobular vein. Some neuropeptides have been identi-
fied, such as vasointestinal peptide, neuropeptide Y, substance P, glucagon, and calcitonin
gene-related peptide. Stimulation of sympathetic fibers causes an increase in vascular
resistance and a decrease in hepatic blood volume.
The Hepatic Portal Tree
Segmental branches of the portal vein split dichotomously into equal sized branches,
constituting a tree of conducting vessels that terminate in venules having an inner diam-
eter of about 400 µm. Each branch of the afferent vessels is essential for proper function
because it supplies blood to a specific area. There are few, if any, anastomoses that could
provide collateral circulation if a major branch is impaired. In other words, the first por-
tion of the portal system is merely conductive up to the branching into preterminal portal
venules with an inner diameter of 80–40 µm. This latter portion appears to be the main
site of the constrictive response of the portal tree to various constrictive stimuli and, as
such, the main mechanism for controlling blood distribution within the liver. Further
downstream, the so-called terminal portal venules are endothelial tubes surrounded by
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a thin layer of smooth muscle. These structures do not contract and splits into septal,
perilobular, and lobular branches that supply directly blood to sinusoids via inlet venules
and give a constant but sluggish blood flow (12). At this last level, a sphincter mech-
anism is created by the nuclei of endothelial cells residing at origin of sinusoids. The
branching of the distribution portion of portal tree is paralleled by the arterial and lym-
phatic components of the portal tract (13).
Arterial Supply
Arterial supply, which normally represents from 25% to 30% of the hepatic blood
flow, satisfies the oxygen demands of the stromal and parenchymal compartments of the
liver. The arteries form a peribiliary plexus that surrounds and nourishes small bile ducts.
Intrahepatic arteries are thick-walled and become smaller as the arteries branch. Termi-
nal branches contain only endothelium surrounded by a thin adventitia. Entry of arterial
blood into sinusoids takes place at different levels, mainly zone 1 and 2 of the acinus.
Additional entrances in zone 3 have also been postulated. Drainage of the plexus is both
directly in sinusoids and into small branches of the portal veins (14). In physiological
conditions, the arterial flow varies inversely with portal vein flow, and compensates for
the eventual shortage of portal perfusion (15,16). The hepatic artery provides a pulsatile
but small-volume flow that appears to enhance sinusoidal flow, especially in periods of
reactive arterial flow, such as the postprandial hyperemia. The proportion of arterial per-
fusion rises in portal hypertension irrespective of the etiology and reflects a deterioration
of liver conditions (17).
The Functional Unit of the Liver—Rappaport’s Acinus
Rappaport’s acinus is a parenchymal mass lying between two centrilobular veins. Its
axis is a small radicle of the portal triad containing a terminal portal vein (diameter <40
µm), a hepatic arteriole (diameter >15 µm), nerves, lymph vessels, and bile ducts or chol-
angioles. This axis, seldom seen by light microscopy, corresponds to the connective tissue
septa. Blood drain into centrilobular veins (diameter <65 µm) from the terminal branch
of the portal vein. In sinusoids, flow is unidirectional, from periportal to centrilobular
hepatocytes. The concept of functional heterogeneity has been based on this organization.
The acinus is arbitrarily divided into three zones; (zone 1) periportal; (zone 2) mediolobular;
(zone 3) centrolobular (18). In Rappaport’s acinus, blood flows unidirectionally from zone
1 to zone 3. This is because of: (1) the presence of sinusoidal inlet and outlet sphincters
composed of sinusoidal lining cells bulging into the lumen; (2) transient leucocyte plug-
ging; (3) variations in the morphology of sinusoids in the different zones; and (4) the con-
tribution of arterial flow at the beginning of the sinusoidal structures (19).
Sinusoids
Between the genuinely interdigitating networks of afferent and efferent vessels, there
is a space filled with plates and columns of hepatocytes, among which a complex network
of sinusoids is found. In other words, the hepatic sinusoids can be seen as conduits con-
necting the terminal portal venule and terminal hepatic arteriole with the hepatic venules.
The length of a human sinusoid varies between 223 and 477 µm. The average velocity
of erythrocyte flow in sinusoids ranges between 270 and 410 µm/s. Average blood pres-
sure has been measured to be about 4.8 mmHg in terminal portal branches, 30–35 mmHg
in arterial blood, and 1.7 mmHg in collecting vessels (20). The huge cross-sectional area
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of the sinusoids is responsible for the normally low transsinusoidal vessel resistance,
pressure gradient, and flow velocity. It is estimated that 80% of the sinusoidal profile
would have to be obliterated to cause portal pressure to rise (21). This portion of the liver
circulation is unique in comparison to most other capillary beds. Its endothelial lining is
made up of flat, lobulated, fenestrated cells, which overlap loosely without being attached
to one another, i.e., intercellular junctions are absent. In contrast with other capillaries,
hepatic sinusoids are not provided with a basal membrane. The presence of elements of
the cytoskeleton in these fenestrations have raised the issue of whether fenestrations
may contract and to what extent this may influence the passage of solutes into the space
of Disse. This is a space located between the sinusoidal domain of the hepatocyte plasma
membrane and the endothelial cells forming the walls of the hepatic sinusoids.
This space, which is not normally discernible in biopsy material by standard light mic-
roscopy, is characterized by the presence of different components of the extracellular
matrix (different type of collagens mainly type III, but also types I and IV, proteoglycans,
laminin, and fibronectin). Fibrillar collagens such as collagen types I and III are orderly
distributed to form a supporting framework, whereas other components such as collagen
type IV, proteoglycans, and laminin are distributed in order to form a matrix allowing
the exchange of macromolecules between the sinusoidal blood and the hepatocytes. The
caliber of the sinusoids is variable, typically 6–30 µm, but can increase up to 180 µm.
Periportal sinusoids are narrow and tortuous facilitating solute–capillary wall interac-
tion, whereas perivenous sinusoids are straighter and wider. The changes of the caliber
seem to be mostly passive, depending on regional flow and volume changes but depends
also on active contraction of HSC, and changes in the diameter of sinusoidal fenestrations
as it will be further expanded.
There are two types of sphincter-like structures at the entering sites of hepatic sinusoids.
One is located at the junction between the terminal portal venule and the sinusoid, and is
characterized by the large endothelial cells surrounded with Ito cells (HSCs). The other is
located at the junction between the terminal hepatic arteriole and the sinusoid, and cor-
responds to the precapillary sphincter because our enzymohistochemical demonstration
of arterial capillaries in close association with the sinusoids combined with intravital mic-
roscopy has revealed that the terminal hepatic arteriole directly terminates in the sinusoid.
Control of the Intrahepatic Circulation
Under physiological conditions, the liver itself is the main site of resistance to portal
flow. It should be emphasized that there is no precise mechanism regulating portal flow
into the liver and, in normal conditions, the portal tree is able to accept any amount of
blood coming from the splanchnic area. In other words, the liver is not able to control the
volume of the portal flow, which is mainly determined by resistance vessels of splanchnic
organs that drain into the portal venous system. The principal site of resistance within nor-
mal hepatic tissue is still a matter of controversy. There are indeed several structures poten-
tially affecting intrahepatic resistance. These include terminal hepatic venules, small
portal venules, and, at the sinusoidal level, the state of tension developed by HSC around
sinusoids and the number and diameter of sinusoidal fenestrations. However, an active
sinusoidal control of the perfusion still represents a controversial issue, as will be further
expanded. Arterial inflow, on the other hand, is a subject of clear and effective control,
depending mainly on the actual needs of the liver tissue (22). In addition, compensatory
relationships exist between the venous and arterial inflows (23), so arterial flow increases
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when portal flow decreases. This occurs as a result of communications among main ves-
sels, sinusoids, and peribiliary venules (24) that open in response to nervous and soluble
factors (25). In these cases, portal flow blockade has repercussions on the entire territory
downstream from the obstruction, following portal dichotomy and producing an arterial
reaction strictly confined to that territory and, therefore, with a sectorial, triangular shape.
Moreover, in case of bile duct dilatation, a collapse of the peribiliary plexus that sur-
rounds biliary tree like a meshwork and lacks muscular walls is observed. Because this
plexus provides an additional flow of portal blood toward the sinusoids, its impairment
or failure results in a further decrease in the total amount of portal blood reaching the
sinusoids and increase in arterial inflow of these structures.
BIOLOGY OF PORTAL CELLS
INCLUDING SINUSOIDAL ENDOTHELIAL CELLS AND HSCs
Sinusoidal Endothelial Cells (SECs)
Liver sinusoidal endothelial cells (SEC) form a continuous lining of the liver capil-
laries, or sinusoids, separating parenchymal cells and HSC from sinusoidal blood. SEC
differ in fine structure from endothelial cells lining larger blood vessels and from other
capillary endothelia in that they lack a distinct basement membrane and also contain
open pores, or fenestrae, in the thin cytoplasmic projections that constitute the sinusoidal
wall (26). This distinctive morphology supports the protective role played by liver endo-
thelium, the cells forming a general barrier against pathogenic agents and serving as a
selective sieve for substances passing from the blood to parenchymal and HSC, and vice
versa. Another functional characteristic of SEC is their high endocytotic capacity. This
function is reflected by the presence of numerous endocytotic vesicles and by the effec-
tive uptake of a wide variety of substances from the blood by receptor-mediated endocy-
tosis (27). This capacity, together with the presence of fenestrae and the absence of a
regular basal lamina, makes these cells different and unique from any other type of endo-
thelial cell in the body. Accordingly, SEC can be regarded as a “scavenger system,” which
clears the blood from many different macromolecular waste products that originate from
turnover processes in different tissues.
Beside endocytosis, endothelial transport in the liver sinusoidal endothelium occurs
through fenestrae without a diaphragm. During this process, the endosomal and lysoso-
mal compartments are bypassed. The exchange of fluids, solutes, and particles is bidirec-
tional, allowing an intensive interaction between the sinusoidal blood and the microvillus
surface of the parenchymal cells. Endothelial fenestrae measure between 150 and 175
nm in transmission electron microscopic preparations, occur at a frequency of 9–13 per
µm2, and occupy about 10% of the wall surface. They are large in zone 1 and smaller but
more numerous in zone 3. Endothelial fenestrae do not obstruct most plasmatic macro-
molecules and enable the exchange of free water and substance within the sinusoids at
quite low hydrostatic pressure (2–3 mmHg).
Fenestrae are dynamic structures whose diameter and number vary in response to a
variety of hormones, drugs, toxins, diseases, or even to changes in the underlying extracel-
lular matrix. Structural integrity of the fenestrated sinusoidal liver endothelium is essen-
tial for the maintenance of a normal exchange of fluids, solutes, particles, and metabolites
between the hepatocytes and sinusoidal blood. Changes in the structure and function of
fenestrae can have adverse effects on hepatocytes and liver function in general (28).
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Sinusoidal fenestrations can change in size in response to various stimuli, including blood
pressure, neural impulses, serotonin, endotoxin, alcohol, and nicotine.
Several studies have explored the mechanisms whereby hormones and cytoskeletal-
altering drugs change the fenestral diameter and number. From these studies it became
clear that drugs which alter the calcium concentration within SEC also change the fenes-
trae diameter (29). Recent data indicate that both Ca2+Mg2+-ATPase and Ca2+ pump-
ATPase demonstrated on the SEC plasma membrane may be involved in the regulation
of intracytoplasmic Ca2+ concentration (30). Other studies have shown that drugs which
interfere with the SEC-cytoskeleton mainly alter the number of fenestrae (31). Finally,
peculiar reports appeared describing fenestral dynamics in various pathological condi-
tions of the liver, such as hypoxia, increasing venous pressure, irradiation, cold storage,
and invasion of the liver by metastatic tumor cells or viruses (26).
Some aspects of SEC function may have relevant implications for the regulation of
sinusoidal pressure. The filtration of lipoproteins by open pores is the simplest mecha-
nism for steric selection. However, the fenestrae limit the free access to the parenchymal
cell by a factor of 10. To overcome the difficulty of bringing solutes and (lipid) particles
into the space of Disse and in contact with the parenchymal cells, the mechanisms of
“forced sieving” and “endothelial massage” has been postulated (28). The hypothesis of
“forced sieving” is based on the consideration that red blood cells unilaterally restrict
the space in which lipoproteins move in Brownian motion. Red blood cells therefore
increase the chance that lipoprotein droplets will escape through the fenestrae. Taking
into account that red blood cells pass by in endless numbers while gently touching the
fenestrated lining and, in the meantime, constantly adapting their shape to the dimensions
of the sinusoid, it is assumed that red blood cells in their turn exert an important effect
on the passage of any molecule larger than water through the liver sieve. According to
the hypothesis of endothelial massage, white blood cells plug the sinusoid because they
have an average size of 8.5 µm and, therefore, do not fit into a sinusoid, which measures
from 5.9 µm in the portal region to 7.1 µm in the centrilobular region. In addition, white
blood cells are less plastic than other blood cells and do not easily adapt to obstacles or
diameter changes of sinusoids. As a result, white blood cells distend the fenestrated endo-
thelium and the space of Disse. As a consequence, fluid in the space of Disse is pushed
downstream and when fenestrae are encountered, fluid will be flushed out of Disse’s
space. After passage of the white blood cells, the space of Disse resumes its original shape,
which causes a suction of fresh fluids into the space. In this way, the homeostasis of sinu-
soidal pressure is maintained by dispersion of lateral force throughout the sinusoidal
sieve. It is implicit that a consistent loss of fenestrations, as it is observed in capillarized
sinusoids, represents per se, an initial cause of deregulation of this homeostasis and of
increased portal pressure.
HSC
HSC are located in the space of Disse in close contact with hepatocytes and SEC. In
human liver, HSC are disposed along the sinusoids with a nucleus-to-nucleus distance
of 40 µm, indicating that the sinusoids are equipped with HSC at certain fixed distances
(32). These observations suggest that, although the total number of HSC constitutes a
small percentage of the total number of liver cells (approx 5–8%), their spatial disposi-
tion and spatial extension may be sufficient to cover the entire hepatic sinusoidal micro-
circulatory network. The most evident ultrastructural feature of HSC in normal adult
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liver is the presence of cytoplasmic lipid droplets ranging in diameter from 1 to 2 µm
(i.e., “fat-storing cells” or “lipocytes”) (32). These lipid droplets are involved in the hep-
atic storage of retinyl esters because of the key role of HSC in the metabolism and storage
of retinoids.
The role of HSC in the progression of liver fibrosis has extensively been character-
ized. As a consequence of chronic liver tissue damage, HSC, as well as other extracellu-
lar matrix-producing cells (e.g., fibroblasts and myofibroblasts constitutively present in
the portal tract), undergo a process of activation that leads to a phenotype characterized
by increased proliferative, motile, and contractile attitudes.
The recognition that HSC are provided with contractile properties represents a key
acquisition in the knowledge of the biology of this cell type (33). Contraction of activated
HSC occurs in vitro in response to different vasoconstrictors (Table 1). However, this
experimental evidence is likely to be more representative of HSC contractile status in
fibrotic liver, where contraction of activated HSC in response to various stimuli may have
important implications in the pathogenesis of portal hypertension and in the contraction
of mature scar tissue. Following two studies published in 1992 (34,35) demonstrating
the contraction of HSC in response to different vasoconstrictors, the potential involve-
ment of this cell type in the genesis and progression of portal hypertension has been
postulated. Regardless, the potential consequences of the contractile attitude of HSC are
still a matter of controversy and some key questions should be addressed before reaching
superficial conclusions. These include:
1. Do HSC play a role in the regulation of sinusoidal tone in normal liver?
2. Do HSC influence portal pressure in conditions of developing fibrosis and “capillariza-
tion” of sinusoids?
3. Do HSC influence portal pressure in cirrhotic liver?
Table 1
Action of Vasoactive Agents on Hepatic Stellate Cells
Agent Contraction Relaxation [Ca2+]i increase
Endothelin-1 ++++ Coupled
Thrombin ++++ Coupled
Angiotensin-II +++ Coupled
Substance P +++
Adenosine +++ Coupled
Thromboxane +++
Vasopressin ++++ Coupled
Platelet-activating factor + Coupled
Cysteinyl leukotrienes +++ Coupled
Adrenomedullin ++ *
Nitric oxide ++ *
cAMP increasing agents +++ *
Lipo PGE1 ++
Atrial natriuretic peptide +++ *
C-type natriuretic peptide +++ *
*Relaxation associated with an inhibition of vasoconstrictor induced-[Ca2+]i increase.
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Because of their anatomical location, ultrastructural features, and similarities with
pericytes regulating blood flow in other organs, HSC have been proposed to function as
liver-specific pericytes. As already introduced, branches of the autonomic nerve fibers
coursing through the space of Disse show a contact surface with HSC (36), and nerve
endings containing substance P and vasoactive intestinal peptide have been demonstrated
in the vicinity of HSC (37). In both a normal and fibrotic liver, the expression of N-CAM,
a typical central nervous system adhesion molecule detected in hepatic nerves, and the
expression of glial fibrillary acidic protein (GFAP) are restricted, among liver cell types,
to HSC (38). These observations, although reinforcing a potential functional relationship
between the autonomic nervous system and HSC, raise a current key issue concerning
the origin of this cell type, previously considered to be of myogenic origin because of the
expression of desmin and smooth muscle -actin (-SMA). Along these lines, activated
HSC express nestin, a class VI intermediate filament protein originally identified as a
marker for neural stem cells (39). Remarkably, the expression of this cell marker appears
to be restricted to HSC and pericytes of brain parenchyma vessels, among all organ-
specific pericytes. Another neuroendocrine marker suggesting a combination of mesen-
chymal and neural/neuroendocrine features in HSC is synaptophysin, a protein involved
in neurotransmitter exocytosis. Synaptophysin reactivity is present in perisinusoidal stel-
late cells in both human and rat normal liver biopsies and the number of synaptophysin-
reactive perisinusoidal cells is increased in pathological conditions (40). Recent expe-
rimental evidence indicates that rat and human HSC express neurotrophins [including
nerve growth factor (NGF), brain-derived neurotrophin, neurotrophin 3, and neurotrophin
4/5] and neurotrophin receptors (41). This information cannot be advocated to support the
possible neural/neuroendocrine differentiation of HSC because neurotrophins and the
relative receptors have been identified in a variety of mesenchymal cells, such as fibro-
blasts and myofibroblasts, both in normal tissues and in tissues undergoing acute or chronic
wound repair. Expression of neurotrophins in tissues other than the central or peripheral
nervous system has classically been considered to be aimed at stimulation of outgrowth
and maintenance of the peripheral nervous system. However, an increasing number of
experimental reports indicate that the neurotrophin/neurotrophin receptor systems is likely
implicated in biological events such as cell differentiation, proliferation, survival, and
motility. In addition, a significant positive correlation between NGF synthesis e cell con-
tractility, possibly related to the regulation of intracellular calcium homeostasis, has been
reported in vascular smooth muscle cells (42,43). In aggregate, these observations sug-
gest a complex interaction between the pathophysiological role of HSC and the function
of the peripheral nervous system.
Although these evidences suggest a role of HSC in the regulation of sinusoidal blood
flow in normal liver, this issue is still matter of substantial controversy. From the mor-
phological standpoint, some observations argue against the role of HSC in the regulation
of sinusoidal blood flow (44). First, in their in vivo tridimensional disposition, HSC do
not have a stellate form (typical of their aspect in bidimensional culture on plastic) but
rather a “spider-like” appearance (“arachnocytes”) in respect of their small cell body with
a series of radiating and parallel slender processes. According to the authors of these
observations, cells with this tridimensional disposition are not likely to be “contraction
ready.” Additional limitations to effective cell contraction are offered by the spatial limit-
ation of the space of Disse, by the intracytoplasmic presence of lipid droplets that prevent
microfilaments from assembly in a long span, and by the ultrastructural evidence of a
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limited development of contractile filaments in quiescent HSC. Regardless, studies eval-
uating the hepatic microcirculation by intravital microscopy techniques have suggested
that HSC could be involved in the regulation of sinusoidal tone in normal liver (45,46).
Additional matter of debate is provided by studies aimed at quantitating HSC contrac-
tion with techniques able to detect the development of contractile forces in response to
vasoconstrictors (47). The results of these studies indicate that the magnitude and kine-
tics of contraction and relaxation are consistent with the hypothesis that HSC may affect
sinusoidal resistance. However, for understandable technical reasons, these data were
obtained in rat HSC in primary culture 7 d after isolation, when a certain degree of activa-
tion in culture has occurred. In conclusion, although HSC could be proposed as liver-speci-
fic pericytes in reason of their location, spatial distribution, relationship with the peripheral
nervous system, and ultrastructural features, no conclusive evidence is presently avail-
able concerning their role in the regulation of sinusoidal blood flow in physiological
conditions.
MAJOR SIGNALING PATHWAYS RELEVANT
TO ENDOTHELIAL–SMOOTH MUSCLE CELL INTERACTIONS
Several vasoactive agents have been shown to be effective in modulating activated HSC
contractility in culture (see Table 1). The role of two vasoregulatory compounds, namely
endothelin 1 (ET-1) and NO, has been particularly highlighted.
Endothelin
Endothelin-1, a potent vasoactive 21-amino-acid peptide secreted by endothelial as
well as other cell types, has been shown to exert a multifunctional role in a variety of
tissues and cells (48–50), including the liver. Infusion of ET-1 in the isolated perfused
rat liver causes a sustained and dose-dependent increase in portal pressure associated
with increased glycogenolysis and oxygen consumption (51–53). ET-1 stimulates gly-
cogenolysis, phosphoinositide turnover, and repetitive, sustained intracellular calcium
transients in isolated rat hepatocytes (54,55). Other studies indicate that ET-1 may also
have important interactions with liver nonparenchymal cells. Cultured sinusoidal endo-
thelial cells isolated from rat liver have been shown to release ET-1 (56), and preferential
binding sites for ET-1 have been identified, both in vivo and in vitro (57,58), on HSC. As
previously mentioned, ET-1 induces a dose-dependent increase in intracellular free cal-
cium, coupled with cell contraction in this cell type. Importantly, activated rat and human
HSC have been shown to express preproET-1 mRNA (59,60) and to release ET-1 in cell
supernatants in response to agonists such as angiotensin II, PDGF, TGF-, and ET-1 itself
(61), thus raising the possibility of a paracrine and autocrine action of ET-1 (62). ET-1 syn-
thesis in HSC is regulated through modulation of endothelin converting enzyme-1 (ECE-
1), the enzyme that converts precursor ET-1 to the mature peptide, rather than by modu-
lation of the precursor pre-proET-1 (63). Recent evidence suggests that upregulation of
56- and 62-kDa ECE-1 3'-untranslated region (UTR) mRNA binding proteins occurs in
HSC after liver injury and during activation in vitro (64). In addition, transforming growth
factor-1, a cytokine integral to the wound healing reaction, stimulates ET-1 production
by inducing ECE-1 mRNA stabilization.
Overall, it is increasingly evident that the process of HSC activation and phenotypical
modulation is characterized by a close and complex relationship with the ET system. The
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ability to synthesize and release ET-1 is associated with a progressive shift in the relative
predominance of ETA and ETB receptors observed during serial subculture: ETA are pre-
dominant in the early phases of activation, whereas ETB receptors become increasingly
more abundant in “myofibroblast-like” cells (60,65). The upregulation of the ETB recep-
tor is prevented by the incubation of HSC with retinoic acid during the activation process
(66), thus confirming that increased expression of this receptor is part of the phenotypi-
cal modulation of HSC toward the “myofibroblast-like” phenotype.
The shift in the relative ET receptor densities may be directed at differentiating the pos-
sible paracrine and autocrine effects of ET-1 on HSC during the activation process. Indeed,
when HSC are provided with a majority of ETA receptors (early phases of activation),
stimulation with ET-1 causes a dose-dependent increase in cell growth, ERK activity,
and expression of c-fos. These effects, likely related to the activation of the Ras-ERK
pathway, are completely blocked by pretreatment with BQ-123, a specific ETA receptor
antagonist (60), and are in agreement with studies performed in other vascular pericytes
such as glomerular mesangial cells (67). Conversely, in later stages of activation, when the
number of ETB receptors increases, ET-1 appears to induce a prevalent antiproliferative
effect linked to the activation of this receptor subtype (68). In this setting, the activation
of the ETB receptor stimulates the production of prostaglandins, leading to an increase in
intracellular cAMP, which in turn reduces the activation of both ERK and JNK (69). In
addition, both cAMP and prostaglandins upregulate ETB binding sites, thus suggesting
the possibility of a positive-feedback regulatory loop. In addition, recent studies have fur-
ther defined the action of cAMP on the ET-1 receptor system. Cyclic AMP rapidly desen-
sitizes ETA in activated HSC and shifts their ET-1 responsiveness from picomolar to nan-
omolar concentrations with respect to Ca(2+) signals and HSC contraction. ETA desensi-
tization also occurs in response to prostaglandin E2, adenosine, or ETB stimulation (70).
Concerning the potential involvement of HSC in the development of portal hyperten-
sion, it is important to note that, at least in human HSC, ET-1-induced cell contraction
occurs at any stage of HSC activation (60). Because HSC contraction is always blocked
by ETA receptor antagonists and never reproduced by selective ETB agonists, it is con-
ceivable that the signaling pathways regulating HSC contraction require the activation
of a small number of ETA receptors and are somehow divergent from those regulating
cell growth.
In aggregate, these observations suggest that ET-1 may act as a potent vasoconstrictor
agonist regulating intrahepatic blood flow in cirrhotic liver with a potential role in the
pathogenesis of portal hypertension. Along these lines, morphological studies have clearly
indicated that ET-1 (both at mRNA and protein levels) is markedly overexpressed in dif-
ferent cellular elements present within cirrhotic liver tissue, and particularly in sinusoidal
endothelial and HSC in their activated phenotype located in the sinusoids of the regenerat-
ing nodules, at the edges of fibrous septa, and in the ECM embedding neoformed vessels
within fibrous bands (60). In addition, clinical studies indicate that a direct relationship
exists between ET receptor mRNA abundance and the degree of portal hypertension in
cirrhotic patients (71).
NO
NO is a small, relatively stable, free-radical gas that readily diffuses into cells and mem-
branes where it reacts with molecular targets (72). It is important to note that the precise
biochemical reactions, which are realized in any biological setting, depend on the concen-
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tration of NO achieved and often on subtle variations in the composition of the intra- and
extracellular milieu. Accordingly, the biological actions of NO are often defined as a
“double-edged sword.” NO may act as a key signaling molecule in physiological pro-
cesses as diverse as host defense, neuronal communication, and regulation of vascular
tone. On the other hand, excessive or not adequately regulated NO synthesis has been
implicated as causal or contributing to several pathophysiological conditions including
vascular shock, diabetes, and chronic inflammation. Although NO is characterized by a
very short half-life, its biochemical interactions with oxyradicals lead to the production
of longer-lived compounds such as peroxynitrite, with important local effects. NO is pro-
duced from L-arginine by one of the three isoforms of nitric oxide synthase (NOS). The
“constitutive” forms of NOS, which respond to changes in intracellular calcium concen-
tration and typically produces small amounts of NO, are expressed by endothelial cells
and in neurons, whereas a wide variety of other cells express the “inducible” form of this
enzyme, that binds calmodulin at virtually all calcium concentrations and produce remark-
ably higher amounts of NO. The constitutive forms are regulated by hypoxia, shear stretch,
or cytokines, whereas the inducible form is regulated by a large variety of stimuli includ-
ing cytokines and lipopolysaccharide.
Because the intraportal administration of the NOS inhibitor, N-nitro-L-arginine, in-
creases portal pressure (73), NO has been postulated to be a regulator of sinusoidal blood
flow in normal liver. Along these lines, in vitro and in vivo evidence indicate that SEC
express constitutive nitric oxide synthase (eNOS) and produce NO, and increase their pro-
duction in response to flow (74). However, an endothelial dysfunction associated with
a decreased production of NO in the intrahepatic microcirculation has been documented
extensively in cirrhotic liver (75,76), and these defects could directly contribute to the
increased intrahepatic resistance typical of portal hypertension. This view is supported
by experiments performed in vitro and in animal models by gene transfer of the neuronal
NO synthase isoform (nNOS) to sinusoidal endothelial cells or other perisinusoidal cells,
such as HSC (77). Expression of nNOS in rat HSC and sinusoidal endothelial cells resulted
in increased NO production, and, in HSC, in a reduction of ET-1-induced contractility.
Moreover, in two different rat models of cirrhosis and portal hypertension, transduction
of livers with recombinant Ad.nNOS significantly reduced intrahepatic resistance and
portal pressure.
As in the case of ET-1, circumstantial evidence for a relevance of NO in HSC biology
has derived from in vitro studies. Exogenous NO is able not only to prevent ET-1-induced
contraction and to relax precontracted cells, but also to reduce the expression of -SMA
(78). In addition, interferon- and other cytokines with or without lipopolysaccharide,
as well as hyaluronan fragments induce the expression of the inducible form of NOS and
the production of NO in HSC (79,80). However, at least in human HSC, this effect is very
limited and the possibility of an autocrine action of NO in HSC appears merely specula-
tive. In addition to these effects on HSC contraction and contractile proteins, NO has been
shown to reduce the expression of procollagen type I mRNA and the secretion of the
encoded protein (79). Therefore, it is possible that NO may influence the progression of
portal hypertension by reducing the accumulation of fibrillar matrix in key areas such as
the fibrous septa, as suggested by evidence deriving from animal models of liver fibrosis
(81). It is also conceivable that the reduced synthesis of NO, typical of cirrhotic liver,
may further aggravate the fibrogenic progression of the disease and that administration
of orally active NO donors could be proposed as a potential antifibrogenic treatment, as
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suggested by recent studies performed in human HSC (82) and in animal models of liver
fibrogenesis (83).
Studies employing patch-clamp techniques have provided additional information on
the role of membrane ion channels potential relevant for the action of vasoactive agents
in HSC. High-conductance Ca(2+)-activated K(+) [BK(Ca)] channels modulate the effects
of vasoactive factors in contractile cells. This channels were detected in activated human
HSC and may modulate the contractile effect of endothelin-1 and mediate the inhibitory
action of NO (84).
Other Vasoactive Agents
Several studies have evaluated the effects of naturally occurring vasodilators on HSC
contractility. These include atrial natriuretic peptide (ANP) (85) and C-type natriuretic
peptide (CNP) (86). Both of these agents have been shown to reduce HSC contraction in
response by ET-1 or thrombin. In addition, CNP is able to reduce HSC proliferation in-
duced by PDGF-BB (86).
In addition to ET-1, the potential involvement of other vasoconstrictors synthesized
and released within liver tissue has been suggested. Titos et al. (87) have reported that
in cirrhotic rat liver there is an increased synthesis of cysteinyl leukotrienes (LTs). In this
context, hepatocytes exhibit the greatest ability to generate cysteinyl-LTs. It is important
to note that these compounds elicit a strong contractile response in activated HSC. These
findings further reinforce the concept of an imbalance between vasoconstrictor and vaso-
dilator agents within the intrahepatic circulation of cirrhotic liver. Importantly, the con-
centration of vasoconstrictors acting on the intrahepatic microvasculature of cirrhotic
liver may increase as a consequence of clinical or subclinical events such as infections in
the peritoneal cavity, which are clearly associated with a worsening of portal hyperten-
sion and with an increased incidence of variceal bleeding (88). This possibility as well
other clinical possibilities, including the correct use of the drugs currently indicated in
the treatment of portal hypertension (89), should be carefully reconsidered in light of the
current knowledge on the cellular and molecular mechanisms of portal hypertension.
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